In recent years, the Russian veterinary retail market has seen steady double-digit growth in demand for drugs used to treat cardiovascular diseases*. In the first half of 2026, buyers purchased over 17.4 million minimum dosage units (MDU) of such veterinary drugs, which is 28.6% higher than in the same period of 2025. In monetary terms, the market grew by 19.8%, reaching RUB 1.1 billion (at retail prices, including VAT). Last year, sales volume in the category increased by 31.8% compared to 2024, exceeding 30 million MDU worth RUB 1.9 billion, with consumer spending growing by 16.1% compared to 2024.

Active import substitution has greatly contributed to this development, and this process accelerated significantly in 2025, when the share of Russian manufacturers in monetary terms grew to 29.3%. In the first half of 2026, the expansion of local brands continued, allowing them to capture a 34.8% share of the market in ruble terms, marking an almost sevenfold increase in the presence of domestic products in the segment since 2022. This growth is clearly confirmed by the dynamics — during the analyzed period, sales of Russian cardiovascular drugs for animals increased by 58% in physical terms and 53% in value terms compared to the first half of 2025.

In January–June 2026, the competitive environment on the Russian retail veterinary cardiovascular drug market was represented by 40 trademarks from 26 manufacturers. The undisputed leader of the segment remains Vetmedin (INN pimobendan) from Boehringer Ingelheim, with a 57.3% share. Second and third places in the ranking are occupied by Russian pimobendan generics — Pimocardin from Agrovetzashchita (12.6%) and Avecardit from VIK — Animal Health (6.5%). At the same time, the highest dynamics in the top ten brands were demonstrated by another domestic pimobendan generic — Mavedin from Nita-Pharm, whose sales increased threefold over the year. Fourth place is occupied by a drug from the group of agents acting on the renin-angiotensin system (C09) under the brand Nephrospas (INN telmisartan), manufactured by Agrovetzashchita. In the category, the brand holds a 4.7% ruble share, with sales growth recorded at +39.8%.

Against the backdrop of the expansion of Russian manufacturers, the positions of foreign products have noticeably weakened. Of the top ten brands, only two are of foreign origin, and both showed relatively weak dynamics. The annual growth of the leader Vetmedin was only 12% in monetary terms, the lowest result among the leading players. Meanwhile, the Latvian drug Pimopet (GIGI) also worsened its position, dropping to sixth place due to a 46% decline in ruble sales.

Fig. Structure of the Russian Retail Market for Veterinary Cardiovascular Drugs by Imported/Domestic (including online channel), % RUB

*Analyzed groups: C01 — Drugs for heart disease, C09 — Agents acting on the renin-angiotensin system, C03 — Diuretics, C07 — Beta-blockers, B01 — Antithrombotic agents.